Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H17N |
| Molecular Weight | 163.2594 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(N)CC1=CC=C(C)C(C)=C1
InChI
InChIKey=ZSZUWPRERIPUBM-UHFFFAOYSA-N
InChI=1S/C11H17N/c1-8-4-5-11(6-9(8)2)7-10(3)12/h4-6,10H,7,12H2,1-3H3
| Molecular Formula | C11H17N |
| Molecular Weight | 163.2594 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4617 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5007085 |
2.85 null [pIC50] |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:45 GMT 2025
by
admin
on
Mon Mar 31 18:09:45 GMT 2025
|
| Record UNII |
4DB10V9J2I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
102-31-8
Created by
admin on Mon Mar 31 18:09:45 GMT 2025 , Edited by admin on Mon Mar 31 18:09:45 GMT 2025
|
PRIMARY | |||
|
26727
Created by
admin on Mon Mar 31 18:09:45 GMT 2025 , Edited by admin on Mon Mar 31 18:09:45 GMT 2025
|
PRIMARY | |||
|
XYLOPROPAMINE
Created by
admin on Mon Mar 31 18:09:45 GMT 2025 , Edited by admin on Mon Mar 31 18:09:45 GMT 2025
|
PRIMARY | |||
|
4DB10V9J2I
Created by
admin on Mon Mar 31 18:09:45 GMT 2025 , Edited by admin on Mon Mar 31 18:09:45 GMT 2025
|
PRIMARY | |||
|
DTXSID70904041
Created by
admin on Mon Mar 31 18:09:45 GMT 2025 , Edited by admin on Mon Mar 31 18:09:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |